Paricalcitol is a medication used to prevent and treat secondary hyperparathyroidism associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D₂, designed to reduce parathyroid hormone levels and help maintain calcium and phosphorus balance in patients undergoing dialysis. Patented in 1989 and approved for medical use in 1998, Paricalcitol is available in oral and injectable forms.
During the production and storage of Paricalcitol, related compounds and impurities may form, necessitating strict monitoring to ensure drug quality and safety.
High-Performance Liquid Chromatography (HPLC) and other advanced analytical methods are employed to detect and quantify impurities and related substances in Paricalcitol formulations.
Paricalcitol is typically taken during dialysis or as directed by a healthcare provider. For oral formulations, it can be taken with or without food, depending on individual tolerance and medical advice.
Paricalcitol is designed to lower parathyroid hormone levels without significantly increasing calcium and phosphorus levels. However, it can raise calcium levels in some patients, so regular monitoring is recommended.
Paricalcitol is available as an oral capsule or injectable solution. The dosage and method of administration depend on the severity of secondary hyperparathyroidism and the patient’s response to treatment, as determined by a healthcare provider.
No, Paricalcitol is not classified as a controlled substance. It is a prescription medication used under medical supervision.
